Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases

ConclusionsOur study demonstrated that a shorter PSADT, a heavier volume of bone metastases, and a later treatment line before Ra-223 are poor prognostic factors for mCRPC patients. These newly discovered risk factors may help select patients who potentially have long-term OS after Ra-223 treatment.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research